论文部分内容阅读
62例T2DM合并NAFLD患者随机分为观察组和对照组,对照组仅给予控制饮食、运动治疗,观察组除饮食、运动方案同对照组外,给予阿卡波糖50mg、3次/日,餐时嚼服;所有患者在治疗前及治疗后12周测血清谷氨酸转氨酶(ALT)、天冬氨酸转移酶(AST)、空腹血糖(FBG)、餐后2小时血糖(2hBG)、HbA1c、空腹胰岛素(FIns)、甘油三酯(TG)、总胆固醇(TC)、体重指数(BMI),比较每组患者治疗前后和两组治疗后效果。结果:两组患者的ALT、AST、FBG、2hBG、HbA1c、Fins、TG、TC、BMI较治疗前明显改善(P<0.01);与对照组相比,观察组疗效更明显(P<0.01,P<0.05),差异有显著性,服阿卡波糖期间患者无明显副作用出现。结论:阿卡波糖治疗T2DM合并NAFLD安全有效。
Sixty-two T2DM patients with NAFLD were randomly divided into observation group and control group. The control group was given only controlled diet and exercise therapy. The observation group was given acarbose 50 mg, 3 times daily, diet, exercise program and control group While the patients were chewed. All the patients were tested for serum ALT, AST, FBG, 2hBG, HbA1c before and 12 weeks after treatment , Fasting insulin (FIns), triglyceride (TG), total cholesterol (TC) and body mass index (BMI) were compared between the two groups before and after treatment and after treatment. Results: The ALT, AST, FBG, 2hBG, HbA1c, Fins, TG, TC and BMI were significantly improved in both groups (P <0.01) P <0.05), the difference was significant, taking Acarbose patients no obvious side effects. Conclusion: Acarbose treatment of T2DM combined with NAFLD safe and effective.